drugset / Trial / NCT07467447
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
RandomizedParallel-groupSingle-blindTreatment
Summary
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.
Timeline
- Start
- 2026-02-15
- Primary completion
- 2027-03-14
- Completion
- 2028-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retatrutide | Protein / enzyme biologic | 1 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 4 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 8 mg | Subcutaneous |
| Subject | Retatrutide | Protein / enzyme biologic | 12 mg | Subcutaneous |